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Intracerebral hemorrhage (ICH) is the most feared risk of systemic thrombolysis for ST-elevated
myocardial infarction, pulmonary embolism, or acute ischemic stroke. Clinical, radiological, and
pathological evidence suggests that cerebral small vessel disease and, in particular, cerebral amyloid
angiopathy (CAA) may contribute to or in some cases directly underpin thrombolysis-related
intracerebral hemorrhage (TICH) (1). Further developments, particularly in neuroimaging, have
strengthened this hypothesis, hinting at the prospect of identifying biomarkers tomeasure TICH risk
for individual patient groups. Emerging biomarkers for CAA such as lobar cerebral microbleeds (2)
may become increasingly useful for outcome endpoints in clinical trials and patient risk stratification
for TICH (3).
Thrombolysis-related intracerebral hemorrhage is a complex pathophysiological process. For
ischemic stroke patients, a key issue is the location of TICH, i.e., hemorrhage into the area of ischemia
vs. hemorrhage in a remote non-ischemic site (occurring in about 20% of patients with symptomatic
TICH). Classification of TICH has traditionally focused on clinical and radiological features (4),
with less emphasis on whether different mechanisms might be implicated in TICH in remote from
or within the acute infarcted region (5) or whether pathological assessment has occurred.
Coregistered Pittsburgh compound B positron emission tomography (PiB-PET) imaging has
revealed that spontaneous hemorrhage hotspots preferentially occur at locations with increased
amyloid β-protein burden (6). In patients treated with recombinant tissue plasminogen activator
(rt-PA) for acute ischemic stroke, cerebral amyloid β-protein (as detected with PiB-PET) retention
was higher in patients with parenchymal hemorrhage compared to patients without (7). Although
PiB-PET has somewhat poor spatial resolution and cannot reliably resolve parenchymal and cere-
brovascular amyloid β-protein, the finding is probably one of the strongest pieces of radiological
evidence implicating CAA in TICH. Matrix metalloproteinase 9, a zinc-dependent endopeptidase
and a marker of hemorrhagic transformation after ischemic stroke, is released from neutrophil
granules by rt-PA in humans (8). Amyloid β-protein can also release and activate MMP-9 from
mouse endothelial cells (9), suggesting that convergent risk factors may lead to hemorrhage.
Cerebral microbleeds identified on MRI in a lobar distribution are considered a characteristic
hemorrhagic marker of a vasculopathy related to CAA (2). It has slowly emerged that multiple
microbleeds might increase the risk of symptomatic ICH following thrombolysis treatment, a
relationship which increases with increasing numbers of microbleeds (10, 11). In more recent
studies with larger groups of ischemic stroke patients receiving intravenous thrombolysis in both
European and Chinese populations, multiple cerebral microbleeds were more clearly associated
with symptomatic and parenchymal hemorrhage, respectively (12, 13). Future study may provide
insights into potential mechanisms, and meta-analyses may highlight the relative importance of
lobar and non-lobar cerebral microbleeds in stratifying the intracerebral hemorrhagic risk from
thrombolysis.
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In a review in 2004 (1), we identified 10 patients with patho-
logical investigation of TICH, 7 of whom had evidence of CAA.
All of these patients had been treated for acute myocardial
infarction and nine of the patients had multiple hemorrhages in
a lobar distribution. With an increasing emphasis on primary
percutaneous intervention for ST-elevated myocardial infarc-
tion, it may not be surprising that no further TICH cases fol-
lowing thrombolysis for acute myocardial infarction have been
reported. However, although thrombolysis rates have increased
for acute ischemic stroke patients, in an updated systematic lit-
erature search, only two further autopsy TICH cases (multiple
and both hemispheres) have been reported in the stroke litera-
ture, both of whom had CAA (14). The relative lack of human
pathological studies compared to neuroimaging studies ham-
pers further developments in this area. A pathological register
attached to a clinical register would enhance our understanding
of TICH, particularly in the older population with acute ischemic
stroke.
The known predictors of clinically significant TICH currently
include age, clinical stroke severity, high blood pressure, hyper-
glycemia, early CT ischemic changes, large baseline diffusion
lesion volume, leukoaraiosis, and cerebral microbleeds on MRI;
the evidence for a role of CAA in TICH continues to accumulate.
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